Proxy Report - 22/06/2018
La société propose un vote sur les politiques de rémunérations 2018 des dirigeants (résolutions 16 à 18). Cependant, elle ne présente pas les montants en jeu pour ledit exercice, rendant ainsi impossible toute estimation des montants totaux en jeu ou de la structure de rémunération mise en place par la société.
De la même façon, la société propose d'approuver les rémunérations 2017 de ses dirigeants mais ne communique ni la nature des indicateurs utilisés dans le cadre du calcul du bonus annuel ni leurs taux de réalisation individuels, rendant impossible pour l'actionnaire de comprendre comment les montants attribués ont été déterminés. Ce manque flagrant d'information (assez rare pour une société du SBF120) ne permet pas de soutenir les résolutions 13 à 15.
DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.